Bupropion HCL ER (XL)

FDA Drug Profile — Bupropion HCL ER (XL)

Bupropion HCL ER (XL) is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including Bupropion HCL ER (XL). Available dosage form: tablet, extended release.

Drug details

Generic Name
Bupropion HCL ER (XL)
Brand Names
Bupropion HCL ER (XL)
Application Number
ANDA210015
Sponsor
Direct_RX
NDC Codes
3
Dosage Forms
TABLET, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
BUPROPION HYDROCHLORIDE

Indications and Usage

1.1 Major Depressive Disorder (MDD) Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see CLINICAL STUDIES (14.1)]. 1.2 Seasonal Affective Disorde (SAD) Bupropion hydrochloride extended-release tablets (XL) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD). The efficacy of bupropion hydrochloride extended-release tablets (XL) in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials in adult outpatients with a history of MDD with an autumn-winter seasonal pattern as defined in the DSM [see CLINICAL STUDIES (14.2)].

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.